
1. j gastroenterol. 2012 sep;47(9):1014-21. doi: 10.1007/s00535-012-0560-9. epub
2012 mar 2.

randomized trial peginterferon α-2a plus ribavirin versus peginterferon α-2b
plus ribavirin chronic hepatitis c japanese patients.

miyase s(1), haraoka k, ouchida y, morishita y, fujiyama s.

author information: 
(1)department gastroenterology hepatology, ntt west kyushu hospital,
1-17-27 shinyashiki, kumamoto 862-8655, japan. sho@ntthosp.jp

background: pegylated interferon (pegifn) plus ribavirin standard therapy 
for patients chronic hepatitis c genotype 1. although several randomized
clinical trials compared pegifnα-2a pegifnα-2b, 2 regimens have
not directly compared asian patients. we, therefore, compared safety 
and antiviral efficacy agents japanese patients.
methods: total 201 pegifn-naïve, chronic hepatitis c patients randomly 
assigned once-weekly pegifnα-2a (180 μg) pegifnα-2b (60-150 μg) plus
ribavirin. compared sustained virological response (svr) rates the
2 regimens analyzed effects relation baseline characteristics,
including single nucleotide polymorphisms (snps) near interleukin-28b (il28b)
gene (rs8099917).
results: pegifnα-2a associated higher svr rate pegifnα-2b (65.3
vs. 51.0%, p = 0.039). pegifnα-2a snps near il28b independently predicted svr
(odds ratio 2.36; 95% confidence interval [ci] 1.19-15.50, odds ratio 7.31;
95% ci 3.45-4.68, respectively) logistic regression analysis. pegifnα-2a was
more effective pegifnα-2b (81.8 vs. 62.7%, p = 0.014) il28b tt genotype
patients, despite similarly low svr rates patients tg gg genotypes
(36.4 vs. 35.9%). patients weighing <60 kg, women, patients aged >60 years
had significantly higher svr rates pegifnα-2a pegifnα-2b (63.9,
61.3, 67.3% vs. 43.8, 43.3,and 39.2%, respectively).
conclusions: pegifnα-2a plus ribavirin resulted higher svr rates than
pegifnα-2b plus ribavirin japanese patients. pegifnα-2a-based treatment should
therefore preferred choice women, older low-weight patients, and
those il28b tt genotype.

doi: 10.1007/s00535-012-0560-9 
pmid: 22382633  [indexed medline]

